Medicare expands home infusion access, but adds payment penalties for remote care

What it does

This bill expands Medicare coverage for home infusion therapy by adding pharmacy services to the list of covered services, allowing nurse practitioners and physician assistants (not just doctors) to establish and review treatment plans, extending coverage to non-pump drugs like antibiotics and antivirals, and adjusting payment rates. Starting January 1, 2026, Medicare will pay for infusion services even when a supplier is not physically present (at 50% of the normal rate), and will no longer separately reimburse for basic supplies like tubing and syringes when they are furnished with the infusion drug on the same day.

Why we flagged it

The bill's core function is to broaden Medicare coverage for home infusion therapy—adding pharmacy services, expanding eligible practitioners, including non-pump drugs, and restructuring payment. This is a straightforward healthcare access expansion, not a carve-out or deregulation.

What the text implies

• The 50% payment reduction for remote administration (when supplier not physically present) may incentivize in-person visits even when clinically unnecessary, potentially increasing costs and patient burden.
• Bundling of supplies with infusion drugs eliminates separate reimbursement for tubing, catheters, and dressings—suppliers may absorb costs or shift them to patients if not covered under the consolidated rate.
• Expansion to non-pump antibacterial, antifungal, and antiviral drugs significantly broadens the scope of home-based IV therapy, potentially reducing hospital admissions but also increasing demand for home infusion suppliers and nursing oversight.
• Allowing nurse practitioners and physician assistants to establish and review plans of care (not just physicians) may improve access in underserved areas but could create inconsistency in clinical oversight if training and credentialing standards vary.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Patients gain expanded access to home infusion therapy (including non-pump drugs), broader practitioner eligibility to manage care, and reduced out-of-pocket costs through consolidated billing. The 50% payment reduction for remote administration and supply bundling may create minor friction, but the net effect is broader, more flexible, and more affordable home-based care.

Who stands to gain

• home infusion therapy suppliers
• pharmacy benefit managers
• durable medical equipment (DME) suppliers
• nursing and clinical staffing agencies

Named in the bill

Medicare, Social Security Act, home infusion therapy suppliers, nurse practitioners, physician assistants, US Pharmacopeia, HCPCS codes (A4221, A4222, K0552)

Where it stands

1 cosponsor: 1 Republicans.

• Mar 13, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Mar 13, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

7 lobbying clients named this bill on 9 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,574,000 in lobbying spend. A filing names 47 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 86% of bills with at least one filing.

Mark Warner, the sponsor, reported $2,246,650 in PAC receipts in the 2026 cycle.

• American Association of Nurse Practitioners — $950,000 on 2 filings
• American Nurses Association — $270,000 on 1 filing
• Premier, Inc. — $140,000 on 1 filing
• National Home Infusion Association — $80,000 on 1 filing
• Option Care Enterprises, Inc. — $80,000 on 2 filings

Lobbying Disclosure Act filings through Jul 22, 2026. A filing shows who paid to lobby on a bill it names, not what changed.